KR102485587B1 - a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method - Google Patents
a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method Download PDFInfo
- Publication number
- KR102485587B1 KR102485587B1 KR1020200005790A KR20200005790A KR102485587B1 KR 102485587 B1 KR102485587 B1 KR 102485587B1 KR 1020200005790 A KR1020200005790 A KR 1020200005790A KR 20200005790 A KR20200005790 A KR 20200005790A KR 102485587 B1 KR102485587 B1 KR 102485587B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- fermented
- porridge
- tang
- parts
- Prior art date
Links
- 239000009536 samultang Substances 0.000 title claims abstract description 58
- 230000036039 immunity Effects 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 29
- 235000014347 soups Nutrition 0.000 title 2
- 235000021395 porridge Nutrition 0.000 claims abstract description 98
- 230000002708 enhancing effect Effects 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 241000212948 Cnidium Species 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 6
- 244000199866 Lactobacillus casei Species 0.000 claims description 6
- 244000170916 Paeonia officinalis Species 0.000 claims description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 6
- 241000031670 Saccharopolyspora thermophila Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 235000011511 Diospyros Nutrition 0.000 claims description 3
- 244000236655 Diospyros kaki Species 0.000 claims description 3
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 3
- 240000008790 Musa x paradisiaca Species 0.000 claims description 3
- 235000015266 Plantago major Nutrition 0.000 claims description 3
- 240000006079 Schisandra chinensis Species 0.000 claims description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000012360 testing method Methods 0.000 description 36
- 230000001965 increasing effect Effects 0.000 description 27
- 230000001506 immunosuppresive effect Effects 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 229960004397 cyclophosphamide Drugs 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 240000007594 Oryza sativa Species 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 235000007164 Oryza sativa Nutrition 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 235000009566 rice Nutrition 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000008935 nutritious Nutrition 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000000702 aorta abdominal Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001995 reticulocyte Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000021329 brown rice Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940099472 immunoglobulin a Drugs 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 240000001810 Angelica gigas Species 0.000 description 2
- 235000018865 Angelica gigas Nutrition 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 240000002045 Guettarda speciosa Species 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 면역력 증진 기능이 있는 죽에 관한 것으로, 특히 발효사물탕을 일반죽에 포함하여 면역력 증진 기능을 현저히 증진시킨 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽에 관한 발명이다.
본 발명은 통상의 죽에 발효사물탕이 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.
또한 본 발명은 상기한 발효사물탕은 통상의 죽에 0.01~20%(중량%)가 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.
또한 본 발명은 죽을 준비하는 과정(1과정),
발효사물탕을 준비하는 과정(2과정),
상기에서 준비한 죽과 발효사물탕을 혼합하는 과정(3과정),
을 포함하여 구성된 면역력 증진 기능이 있는 발효사물탕 죽의 제조 방법을 제공한다.The present invention relates to porridge with an immunity-enhancing function, and in particular, a method for manufacturing fermented samul-tang porridge with an immunity-enhancing function, which significantly improves the immunity-enhancing function by including fermented samul-tang in general porridge, and the resulting fermented samul-tang with an immunity-enhancing function. It is an invention about porridge.
The present invention provides fermented samul-tang porridge with an immunity-enhancing function, characterized in that normal porridge contains fermented samul-tang.
In addition, the present invention provides fermented samul-tang porridge with immunity enhancing function, characterized in that the above-mentioned fermented samul-tang contains 0.01 to 20% (% by weight) in normal porridge.
In addition, the present invention is a process of preparing porridge (step 1),
The process of preparing fermented sugar tang (2 processes),
The process of mixing the porridge prepared above with fermented samul-tang (step 3),
It provides a method for producing fermented sugar-tang porridge having an immunity enhancing function comprising a.
Description
본 발명은 면역력 증진 기능이 있는 죽에 관한 것으로, 특히 발효사물탕을 일반죽에 포함하여 면역력 증진 기능을 현저히 증진시킨 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽에 관한 발명이다.The present invention relates to porridge with an immunity-enhancing function, and in particular, a method for manufacturing fermented samul-tang porridge with an immunity-enhancing function, which significantly improves the immunity-enhancing function by including fermented samul-tang in general porridge, and the resulting fermented samul-tang with an immunity-enhancing function. It is an invention about porridge.
죽은 일반 쌀(백미)을 주재료로 하고 개인의 기호도에 따라 해물류, 야채류 등과 다량의 물을 가하여 장시간 끓여 만드는 음식으로, 주로 유아, 노약자, 환자 등의 주식 대용으로 널리 이용되어 왔다. 죽은 영양 공급, 갈증 해소, 체질 개선, 체력 증강 등의 효과를 지니고 있을 뿐 아니라 이뇨 작용, 체중 완화 등에도 효과가 있고 다른 식품의 소화 및 흡수에도 도움을 주는 것으로 알려져 있다.Porridge is a food made by boiling ordinary rice (white rice) as the main ingredient and adding seafood, vegetables, etc., and a large amount of water according to individual preference, and has been widely used as a substitute for stock for infants, the elderly, and patients. It is known that porridge not only has effects such as supplying nutrients, quenching thirst, improving constitution, and enhancing physical strength, but also has effects such as diuretic action and weight reduction, and helps digestion and absorption of other foods.
일반 쌀에는 열량원이 되는 당질이 풍부하게 함유되어 있지만, 식물섬유, 무기질, 비타민 등의 필수 영양소 함유량이 부족하여 체력이 부족한 유아, 노약자, 환자 등에게 영양학적으로 균형이 맞지 않으며, 백미를 주식으로 하는 이용자에게는 건강에 있어 영양소의 불균형한 문제가 대두될 수 있으며, 특히 체력이 극히 부족한 환자들에게는 새로운 영양 공급원이 필요하다.Although regular rice is rich in sugar, which serves as a source of calories, it lacks essential nutrients such as dietary fiber, minerals, and vitamins, so it is nutritionally unbalanced for infants, the elderly, and patients who lack physical strength, and white rice is a staple food. For users who do this, an imbalanced problem of nutrients may emerge, and new sources of nutrition are needed, especially for patients with extremely poor physical strength.
최근에는 소비자의 맛에 대한 욕구 이외에도 웰빙 자연건강식품에 대한 요구가 꾸준히 증가하고 있어 영양을 강화하거나 기능성을 부여한 죽에 대한 개발이 요구되고 있다.In recent years, in addition to consumers' desire for taste, the demand for well-being natural health food is steadily increasing, so the development of porridge with enhanced nutrition or functionality is required.
관련된 특허문헌으로는 대한민국 등록특허 제1678084호에서 코코넛 열매를 이용한 죽 제조방법을 개시하였으며, 대한민국 등록특허 제1573659호에서 노각나무 추출물이 함유된 기능식 죽의 제조방법을 보고하였으며, 대한민국 등록특허 제1578795호에서는 즉석 건조 전복 해산물 죽의 제조방법을 개시하였으며, 대한민국 등록특허 제10-1620686호에서는 삼백초와 오색현미가 첨가된 바지락 죽의 제조방법을 개시한 바 있다.As for related patent documents, Korean Patent No. 1678084 discloses a method for manufacturing porridge using coconut fruit, and Korean Patent No. 1573659 reports a method for manufacturing functional rice porridge containing quinoa extract, and Korean Patent No. No. 1578795 discloses a method for producing instant dried abalone seafood porridge, and Korean Patent Registration No. 10-1620686 discloses a method for producing clam porridge with 300 seconds and five-colored brown rice added.
특히, 최근에는 노인, 약자, 환자 또는 어린이 등의 면역력 개선을 위한 기능성 죽에 관하여 활발한 개발을 진행하고 있다.In particular, in recent years, active development has been conducted with respect to functional porridge for improving the immunity of the elderly, the weak, patients, or children.
관련된 선행기술로 등록특허 10-1886851(방풍 피고막 죽의 제조방법 및 이에 따라 제조된 방풍 피고막 죽)이 제시된바 있다.As a related prior art, Registered Patent No. 10-1886851 (Method for manufacturing windproof film porridge and windproof film porridge prepared accordingly) has been proposed.
상기한 종래기술 및 선행기술은 그 기능이 종래의 죽보다는 효과가 있으나, 면역력 증진 기능성은 없거나 현저히 떨어지는 문제점이 있어, The above-described prior art and prior art are more effective than conventional porridge, but have a problem that there is no immunity enhancing function or is significantly inferior,
본 발명은 면역력 개선 효과가 현저히 높은 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽을 제공하고자 한다.An object of the present invention is to provide a method for manufacturing fermented samul-tang porridge having a remarkably high immunity-enhancing function and fermented samul-tang porridge having an immunity-enhancing function.
또한 본 발명은 항산화 작용 및 항염증 효과가 현저히 높은 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽을 제공하고자 한다.In addition, the present invention is to provide a method for producing fermented samul-tang porridge having an immunity-enhancing function with significantly high antioxidant and anti-inflammatory effects, and fermented samul-tang porridge having an immunity-enhancing function accordingly.
또한 본 발명은 발효사물탕을 이용하여 죽을 제조하는 것으로서 항암 효능 및 혈액 순환 기능에 현저한 효과가 나타나는 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽을 제공하고자 한다.In addition, the present invention is to prepare porridge using fermented samul-tang, and to provide a method for producing fermented samul-tang porridge with an immunity-enhancing function, which has a significant effect on anti-cancer efficacy and blood circulation function, and fermented samul-tang porridge with an immunity-enhancing function accordingly.
본 발명은 상기한 목적 및 요구를 해결하기 위하여 통상의 죽에 발효사물탕이 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.The present invention provides fermented samul-tang porridge having an immunity enhancing function, characterized in that fermented samul-tang is included in normal porridge in order to solve the above objects and needs.
또한 본 발명은 상기한 발효사물탕은 통상의 죽에 0.01~20%(중량%)가 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.In addition, the present invention provides fermented samul-tang porridge with immunity enhancing function, characterized in that the above-mentioned fermented samul-tang contains 0.01 to 20% (% by weight) in normal porridge.
또한 본 발명은 죽을 준비하는 과정(1과정),In addition, the present invention is a process of preparing porridge (step 1),
발효사물탕을 준비하는 과정(2과정),The process of preparing fermented sugar tang (2 processes),
상기에서 준비한 죽과 발효사물탕을 혼합하는 과정(3과정),The process of mixing the porridge prepared above with fermented samul-tang (step 3),
을 포함하여 구성된 면역력 증진 기능이 있는 발효사물탕 죽의 제조 방법을 제공한다.It provides a method for producing fermented sugar-tang porridge having an immunity enhancing function comprising a.
본 발명에 따른 면역력 증진 기능이 있는 발효사물탕 죽은 종래기술 및 선행기술의 죽보다 면역력 증진 기능이 현저히 높은 효과가 나타난다.Fermented samul-tang porridge with immunity-enhancing function according to the present invention shows a significantly higher immunity-enhancing function than porridge of the prior art and prior art.
또한 본 발명에 따른 면역력 증진 기능이 있는 발효사물탕 죽은 항산화 작용 및 항염증 효과가 현저히 높은 효과가 나타난다.In addition, the fermented samul-tang porridge having an immunity enhancing function according to the present invention exhibits remarkably high antioxidant and anti-inflammatory effects.
또한 본 발명에 따른 면역력 증진 기능이 있는 발효사물탕 죽은 항암 효능 및 혈액 순환 기능에 현저한 효과가 나타난다.In addition, the fermented samul-tang porridge with immunity enhancing function according to the present invention has a remarkable effect on anti-cancer efficacy and blood circulation function.
또한 본 발명에 따른 면역력 증진 기능이 있는 사군자탕 죽은 죽 본래의 맛을 유지하면서도 소화력도 높은 효과가 나타난다.In addition, Sagunjatang porridge with an immunity enhancing function according to the present invention maintains the original taste and has a high digestibility effect.
도 1 내지 도 24는 본 발명에 따른 면역력 증진 기능이 있는 발효사물탕 죽에 대한 동물 시험에서의 면역력 개선 효과를 보여주는 도면.1 to 24 are diagrams showing the immunity improvement effect in animal tests for the fermented sugar-tang porridge having an immunity enhancing function according to the present invention.
이하 본 발명을 도면을 참고하여 상세히 설명하고자 한다.Hereinafter, the present invention will be described in detail with reference to the drawings.
본 발명은 통상의 죽에 발효사물탕을 혼합한 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.The present invention provides fermented samul-tang porridge with immunity enhancing function by mixing fermented samul-tang with normal porridge.
본 발명의 상기한 통상의 죽은 일반적인 쌀(백미 또는 현미)를 이용하여 제조한 죽을 의미하는 것으로 백미죽, 현미죽 또는 육류, 버섯 또는/및 해산물을 함유하여 제조한 죽 등을 포함하는 개념이다.The above-described conventional porridge of the present invention means porridge prepared using common rice (white or brown rice), and is a concept including white rice porridge, brown rice porridge, or porridge containing meat, mushrooms, or / and seafood.
본 발명의 상기한 죽은 고형물이 20~99% 정도 포함되고 나머지는 물로 이루어진 죽을 의미한다.The porridge of the present invention means a porridge containing about 20 to 99% of the solids and the remainder consisting of water.
본 발명은 죽을 준비하는 과정을 수행한다.(1과정)The present invention performs the process of preparing porridge. (Step 1)
본 발명의 죽은 다음과 같은 실시예로 제조할 수 있다.The porridge of the present invention can be prepared in the following examples.
먼저, 백미를 물에 불린 후 준비한다.First, prepare white rice after soaking it in water.
물 1000중량부에 백미 200~900중량부를 바람직하게는 700중량부를 혼합하여 센불에서 끓여준다. 끓어 오르면 중불에서 4~7분정도 더 끓여준다. 눌러 붙지 않게 저어주면서 약불로 4~7분 정도 더 끓여 영양죽을 제조한다.Mix 200 to 900 parts by weight of white rice with 1000 parts by weight of water, preferably 700 parts by weight, and boil over high heat. When it boils, simmer for another 4-7 minutes over medium heat. While stirring to prevent sticking, boil for another 4 to 7 minutes over low heat to make nutritious porridge.
본 발명은 발효사물탕을 준비하는 과정을 수행한다.(2과정)The present invention performs the process of preparing fermented sugar-tang. (Step 2)
본 발명의 상기한 발효사물탕은 숙지황, 작약, 천궁, 당귀를 혼합하여 추출한 조성물을 발효균을 접종하여 발효시킨 것을 의미한다.The fermented samul-tang of the present invention means that a composition obtained by mixing and extracting Sukjihwang, Peony, Cnidium, and Angelica is inoculated with fermenting bacteria and fermented.
본 발명은 숙지황, 작약, 천궁, 당귀를 혼합하여 추출한 조성물을 준비하는 과정을 수행한다.(2-1과정)In the present invention, a process of preparing a composition extracted by mixing Sukjihwang, Peony, Cnidium, and Angelica is performed. (Step 2-1)
본 발명은 상기한 숙지황 100중량부에 작약 50~150중량부, 천궁 50~150중량부, 당귀 50~150 중량부를 혼합하여 조성한 것이 항산화, 항염 및 면역 효능에 최적의 효과가 있다.In the present invention, a mixture of 50 to 150 parts by weight of Peony, 50 to 150 parts by weight of Cnidium, and 50 to 150 parts by weight of Angelica gigas with 100 parts by weight of the above-mentioned Rehmannia Root has optimal antioxidant, anti-inflammatory and immune effects.
조성물 추출 방법은 물을 혼합하여 가열하거나 알코올을 이용하거나 환류 추출하는 방법을 사용할 수 있다.The composition extraction method may use a method of mixing and heating water, using alcohol, or reflux extraction.
조성물에서 물을 혼합하는 비율은 통상 원재료 중량의 3~20배 정도를 포함하는 것이 좋으며, 알코올을 이용하는 경우도 원재료 중량의 1~20배 정도를 포함하는 것이 좋다.The ratio of mixing water in the composition is usually good to include about 3 to 20 times the weight of the raw material, and when using alcohol, it is good to include about 1 to 20 times the weight of the raw material.
본 발명은 상기한 원재료를 상기한 중량부대로 혼합하고 원재료 전체 100중량부를 기준으로 정제수 500~2000중량부 혼합하여 추출물을 수득할 수 있다.In the present invention, the extract can be obtained by mixing the above raw materials in the above weight unit and mixing 500 to 2000 parts by weight of purified water based on 100 parts by weight of the total raw material.
또한 본 발명은 상기한 재료를 혼합한 원재료 100 중량부를 70~90%(중량%) 주정(알코올) 1000~2000 중량부를 넣고 2~5시간 동안 환류 추출한 것을 여과하여 얻은 액을 Rotary Vacuum evaporator로 감압 농축하여 농축액을 수득하고 이 농축액을 freeze dryer로 동결 건조하여 조성물 분말을 수득할 수 있다.In addition, in the present invention, 100 parts by weight of the raw material mixed with the above materials, 1000 to 2000 parts by weight of 70 to 90% (% by weight) alcohol (alcohol), and reflux extraction for 2 to 5 hours are filtered. Concentrate to obtain a concentrate, and freeze-dry the concentrate with a freeze dryer to obtain a composition powder.
추출한 분말은 원재료 총중량의 2~6%(중량%)로 수득할 수 있다. The extracted powder can be obtained at 2-6% (wt%) of the total weight of the raw material.
본 발명은 상기에서 추출한 조성물에 L.delbruekil, L.acidophilus, L.casei, S.thermophilus 또는/및 Yo-mix의 5가지의 균을 접종시켜서 발효를 시키는 과정을 수행한다.(2-2과정)In the present invention, the composition extracted above is inoculated with five bacteria of L.delbruekil, L.acidophilus, L.casei, S.thermophilus or/and Yo-mix to perform fermentation. (Step 2-2) )
삭제delete
즉, 상기에서 추출한 조성물 각각에 L.delbruekil, L.acidophilus, L.casei, S.thermophilus 또는 Yo-mix의 5가지의 각각의 균을 접종시켜 발효시키는 과정을 수행하는 것을 의미한다.That is, it means that each of the compositions extracted above is inoculated with five bacteria of L.delbruekil, L.acidophilus, L.casei, S.thermophilus or Yo-mix to perform a fermentation process.
또한 상기에서 추출한 조성물 각각에 L.delbruekil, L.acidophilus, L.casei, S.thermophilus 및 Yo-mix의 5가지의 균을 모두 혼합하여 접종시켜 발효시키는 과정을 수행하는 것을 의미한다.In addition, it means that each of the compositions extracted above is mixed with and inoculated with five bacteria of L.delbruekil, L.acidophilus, L.casei, S.thermophilus, and Yo-mix to perform a fermentation process.
혼합비율은 자유롭게 할 수 있으며 균등한 비율로 하는 것이 좋다.The mixing ratio can be freely adjusted, and it is better to use an equal ratio.
상기한 발효 과정은 균을 접종하고 30~40도씨에서 20~138시간 정도 발효시키는 과정을 의미한다.The fermentation process described above refers to a process of inoculating bacteria and fermenting at 30 to 40 degrees Celsius for about 20 to 138 hours.
본 발명은 상기에서 추출한 조성물에 항산화 및 면역 효능을 증진시키는데 효과적인 첨가 조성물을 혼합하여 상기한 접종과정 및 발효과정을 수행할 수 있다.In the present invention, the above inoculation and fermentation processes can be performed by mixing the composition extracted above with an additive composition effective for enhancing antioxidant and immune efficacy.
상기한 첨가 조성물은 둥글레 100중량부에 질경이 50~150중량부, 오미자 50~150 중량부, 맥문동 20~50 중량부, 석창포 20~50중량부, 길경 50~150중량부, 의이인 50~150중량부, 감잎 50~150중량부를 혼합하여 추출한 조성물을 의미한다.The above additive composition is 50 to 150 parts by weight of plantain, 50 to 150 parts by weight of Schisandra chinensis, 20 to 50 parts by weight of Maekmundong, 20 to 50 parts by weight of Seokchangpo, 50 to 150 parts by weight of Gilkyung, and 50 to 150 parts by weight of Uiyin. It means a composition extracted by mixing 50 to 150 parts by weight of persimmon leaves.
상기한 첨가 조성물은 상기의 혼합한 원재료 100중량부를 기준으로 증류수 100~5,000중량부에 넣어 가열하여 추출한 것으로 조성물을 수득할 수 있다.The above additive composition can be obtained by heating and extracting 100 to 5,000 parts by weight of distilled water based on 100 parts by weight of the mixed raw materials.
본 발명은 상기한 발효 과정 후에 추출하는 과정을 수행하여 발효사물탕을 수득하게 된다.(2-3과정)In the present invention, fermented sugar-tang is obtained by performing an extraction process after the fermentation process described above. (2-3 steps)
상기한 발효사물탕을 추출하는 방법은 통상의 추출 방법 또는 rotary vacuum evaporator에서 감압 농축하는 과정으로 수행할 수 있다.The method of extracting the fermented sugar-tang described above may be performed by a conventional extraction method or a process of concentrating under reduced pressure in a rotary vacuum evaporator.
본 발명의 상기한 발효사물탕은 항산화 및 면역에 매우 효과적인 특징을 가지게 된다.The fermented sugar-tang of the present invention has characteristics that are very effective for antioxidant and immunity.
본 발명은 상기에서 준비한 죽과 발효사물탕을 혼합하여 면역력 증진 기능이 있는 발효사물탕 죽을 제조한다.(3과정)In the present invention, fermented samul-tang porridge having an immunity enhancing function is prepared by mixing the porridge prepared above and fermented samul-tang. (3 steps)
본 발명의 면역력 증진 기능이 있는 발효사물탕 죽은 상기한 통상의 죽에 발효사물탕이 0.01~20%(중량%)가 포함된 것을 특징으로 한다.Fermented samul-tang porridge with an immunity enhancing function of the present invention is characterized in that 0.01 to 20% (% by weight) of fermented samul-tang is included in the above-described conventional porridge.
아래와 같은 실시예를 통하여 본 발명의 면역력 증진 기능이 있는 발효사물탕 죽이 면역력 증강에 현저한 효과가 있음을 보여준다.Through the following examples, it is shown that the fermented samul-tang porridge of the present invention having an immunity enhancing function has a remarkable effect on enhancing immunity.
<실시예><Example>
Ⅰ. 면역력 증진 기능이 있는 발효사물탕 죽의 제조I. Manufacturing of fermented sugar-tang porridge with immunity enhancing function
1. 죽의 제조1. Preparation of porridge
백미를 잘 씻어서 물에 불린 후 준비한다.Prepare the white rice after washing it well and soaking it in water.
물 1000중량부에 백미 600~900중량부를 바람직하게는 700중량부를 혼합하여 센불에서 끓여준다. 끓어 오르면 중불에서 4~7분정도 더 끓여준다. 눌러 붙지 않게 저어주면서 약불로 4~7분 정도 더 끓여 영양죽을 제조한다.Mix 600 to 900 parts by weight of white rice with 1000 parts by weight of water, preferably 700 parts by weight, and boil over high heat. When it boils, simmer for another 4-7 minutes over medium heat. While stirring to prevent sticking, boil for another 4 to 7 minutes over low heat to make nutritious porridge.
제조한 영양죽을 분말 건조하여 준비한다.The prepared nutritious porridge is prepared by powder drying.
2. 발효사물탕의 제조2. Manufacture of fermented samul-tang
본 발명은 숙지황 60g, 작약 60g, 천궁 60g, 당귀 60g을 정제수 2400g에 넣고 환류 추출하여 수득한 추출 조성물 360g을 준비한다.In the present invention, 360 g of an extraction composition obtained by putting 60 g of Rehmannia Root, 60 g of Peony, 60 g of Cnidium, and 60 g of Angelica gigas in 2400 g of purified water and reflux extraction is prepared.
또한 상기한 추출 조성물에 L.delbruekil(A), L.acidophilus(B), L.casei(C), S.thermophilus(D) 및 Yo-mix(E)의 5가지의 균을 모두 혼합한 균(F)을 접종하여 발효시키는 과정을 수행한다.In addition, the above extract composition was mixed with all five bacteria of L. delbruekil (A), L. acidophilus (B), L. casei (C), S. thermophilus (D) and Yo-mix (E) (F) is inoculated and fermented.
상기의 발효시킨 것을 3시간 동안 환류 추출한 후 여과액을 얻어 rotary vacuum evaporator에서 감압 농축하여 발효사물탕을 수득하였다.After the fermentation was refluxed for 3 hours, the filtrate was obtained and concentrated under reduced pressure in a rotary vacuum evaporator to obtain fermented samul-tang.
상기 수득한 발효사물탕 농축된 용액을 freeze dryer로 동결 건조하여 분말화(52g 수득)하였으며 동결 건조된 시료는 필요한 농도로 증류수에 희석하여 실험에 사용하였다.The obtained fermented sugar-tang concentrated solution was freeze-dried with a freeze dryer to make powder (52 g obtained), and the freeze-dried sample was diluted in distilled water to the required concentration and used in the experiment.
3. 기능성 발효사물탕 죽의 제조3. Manufacturing of functional fermented sugar-tang porridge
상기에서 제조한 분말죽과 증류수를 혼합하여 분말죽 함량이 10%(중량 %)(이를 10% 영양죽 또는 10% 일반죽 이라고 표시함)인 죽을 제조한다.The powder porridge prepared above and distilled water are mixed to prepare porridge having a powder porridge content of 10% (weight %) (this is indicated as 10% nutritious porridge or 10% general porridge).
상기에서 제조한 10% 영양죽에 상기한 사군자탕 농축분말이 0.25%, 0.5%, 1.0%(중량%)로 포함되도록 농축분말을 포함하여 저, 중, 고 농도의 0.25%, 0.5%, 1.0%의 실험용 기능성 발효사물탕 죽을 제조한다.0.25%, 0.5%, 1.0% of low, medium, and high concentrations, including concentrated powder, so that the 10% nutritional porridge prepared above contains 0.25%, 0.5%, and 1.0% (% by weight) of the concentrated powder of Sagunjatang. of experimental functional fermented samul-tang porridge was prepared.
Ⅱ. 동물실험 II. animal testing
1. 실험동물 및 사육환경 1. Laboratory animals and breeding environment
체중 33.2±1.8 g의 수컷 6주령 ICR mouse를 ㈜ 라온바이오 (경기 용인시)로부터 구입하여 1주간의 사육환경 적응 및 존데 적응 훈련을 한 뒤, 실험에 이용하였다. 실험동물의 사육실 온도는 23±1℃, 습도 50±5%, 명암주기 12시간으로 유지되는 항온, 항습 사육실에서 사육하였다. 사료는 실험동물용 고형사료 (퓨리나, ㈜Purina)를 충분히 공급하였으며, 식수는 제한 없이 공급하였다. A 6-week-old male ICR mouse weighing 33.2 ± 1.8 g was purchased from Raon Bio Co., Ltd. (Yongin-si, Gyeonggi-do) and subjected to breeding environment adaptation and sonde adaptation training for 1 week, and then used in the experiment. The experimental animals were reared in a constant temperature and constant humidity breeding room maintained at 23±1℃, 50±5% humidity, and 12 hours light/dark cycle. For the feed, solid feed for experimental animals (Purina, Inc.) was sufficiently supplied, and drinking water was supplied without restriction.
2. 면역 억제 유발 동물 실험 2. Immunosuppression-induced animal experiments
1) 동물군의 분리 및 약물의 투여 1) Isolation of animal groups and administration of drugs
실험동물은 군당 7마리씩 6그룹으로 나누어 실험을 진행하였다. 0.9% NaCl에 녹인 Cyclophosphamide (Sigma aldrich, Korea)를 150 mg/kg 농도로 100 μL씩 실험 시작일과 3일 후에 두 번 주사하여 면역 억제를 유도하였다. 면역억제제와 동시에 시험물질을 투여하기 시작했으며, 정상대조군 (Normal control, NC)(그래프에서 NC)에는 증류수를 경구 투여(그래프에서 I)하였고, 양성대조군에는 기본 영양죽을 10%의 농도로 경구 투여(그래프에서 PC)하였다. 기본 영양죽에 발효사물탕을 첨가한 시험물질은 10% 농도의 기본 영양죽에 저/중/고의 농도로 각각 0.25% / 0.5% / 1.0%(그래프에서 각각 BL, BM, BH)의 한약재를 첨가하여 경구 투여하였다. 투여 14일 후 24시간 절식시킨 뒤, isoflurane으로 흡입 마취 후 개복하여 복대동맥에서 채혈하고 비장 및 흉선 조직을 적출 하였다. Experimental animals were divided into 6 groups, 7 animals per group, and the experiment was conducted. Cyclophosphamide (Sigma aldrich, Korea) dissolved in 0.9% NaCl at a concentration of 150 mg/kg was injected twice at 100 μL each on the first day and 3 days after the experiment to induce immunosuppression. The test substance was administered at the same time as the immunosuppressant, and distilled water was orally administered to the normal control (NC) (NC in the graph) (I in the graph), and basic nutritional porridge was orally administered at a concentration of 10% to the positive control group. (PC in the graph). The test substance added with fermented samul-tang to the basic nutritious porridge was 0.25% / 0.5% / 1.0% (BL, BM, BH, respectively in the graph) at low / medium / high concentrations in the basic nutritious porridge of 10% concentration, respectively. was added and administered orally. After 14 days of administration, after fasting for 24 hours, inhalational anesthesia with isoflurane was performed, and blood was collected from the abdominal aorta by laparotomy, and spleen and thymus tissues were removed.
2) 일반혈액검사 2) General blood test
일반혈액검사를 위하여 복대동맥으로부터 채혈한 혈액을 항응고제가 들어있는 EDTA tube (BD, USA)에 옮긴 후 미국 임상검사표준연구원 (USA, 2017) 기준에 따라 tube를 6~8회 위 아래로 혼합 후 분석 전까지 자동혼합기에 올려놓고 적혈구 수(red blood cell, RBC), 망상적혈구 수(reticulocyte, RETI) 등의 적혈구 지표와 백혈구 수(white blood cell, WBC), 백혈구 백분율(Differential count of WBC)를 자동혈액분석기(Advia 2120i, SIEMENS, Germany)를 이용하여 분석하였다. For a general blood test, blood collected from the abdominal aorta was transferred to an EDTA tube (BD, USA) containing anticoagulant, and then the tube was mixed up and down 6 to 8 times according to the standards of the US Institute of Standards and Technology (USA, 2017) It is placed on an automatic mixer until analysis, and red blood cell indicators such as red blood cell (RBC) and reticulocyte (RETI), white blood cell (WBC), and differential count of WBC are automatically measured. It was analyzed using a blood analyzer (Advia 2120i, SIEMENS, Germany).
3) 혈액 생화학검사 3) Blood biochemical test
혈액 생화학검사를 위하여 복대동맥으로부터 채혈한 혈액을 응고촉진제가 들어있는 혈청 분리용 튜브인 SST tube (BD, USA)에 옮긴 후 미국 임상검사표준연구원 (USA, 2017) 기준에 따라 tube를 6~8회 위 아래로 혼합 후 실온에 30분간 방치하여 완전히 응고되도록 하였다. 응고된 혈액을 원심분리기 (LABOGENE 1248, Korea)를 이용하여 3000 rpm에서 10분간 원심분리 후 상층의 혈청을 분리하였다. 그 후 자동 생화학 분석기 (AU 680, Beckman Coulter, Germany)를 이용해 혈청 영양학적 지표인 Total protein (T.P), Albumin (ALB), Globulin, Total cholesterol (T-CHO), Triglyceride (TG) , BUN을 측정하였다. For the blood biochemical test, the blood collected from the abdominal aorta is transferred to the SST tube (BD, USA), which is a tube for serum separation containing coagulation promoters, and then the tube is 6-8 according to the standards of the US Institute of Standards for Clinical Laboratory Science (USA, 2017). After mixing up and down, leave it at room temperature for 30 minutes to completely solidify. The coagulated blood was centrifuged at 3000 rpm for 10 minutes using a centrifuge (LABOGENE 1248, Korea), and the upper layer of serum was separated. Then, using an automatic biochemical analyzer (AU 680, Beckman Coulter, Germany), serum nutritional indicators such as Total protein (TP), Albumin (ALB), Globulin, Total cholesterol (T-CHO), Triglyceride (TG), and BUN were measured. did
4) 장기 중량 측정 4) Long-term weight measurement
실험 시작일과 종료일에 실험동물 체중 측정하였으며, 실험동물 희생 후 면역세포의 분화가 일어나는 기관인 흉선 및 비장을 적출 하였다. 각 개체의 체중에 따른 차이를 줄이기 위해 최종 희생 일의 체중에 대한 상대 중량을 산출하여 [표 2]와 같이 백분율(%)로 면역 장기 무게 변화를 나타내었다. The weight of the experimental animals was measured on the start and end days of the experiment, and the thymus and spleen, which are organs where differentiation of immune cells occurs, were removed after the animals were sacrificed. In order to reduce the difference according to the body weight of each individual, the relative weight to the body weight on the final day of sacrifice was calculated, and the change in immune organ weight was shown in percentage (%) as shown in [Table 2].
(% of body weight)Relative Organ Weight
(% of body weight)
5) 비장 세포 분리5) Isolation of splenocytes
실험동물의 희생 후 비장을 적출하여 주변 조직을 제거해준 뒤 반으로 절단하였으며, 약 10 mL의 2% RPMI (Gibco, USA)가 담긴 15 mL cornical tube에 넣어 씻어주었다. Petri dish에 옮긴 후 두 장의 슬라이드를 맞닿아서 압력을 가하고 비벼서 분쇄한 뒤 cornical tube에 닮아 옮겨 4℃, 1700 rpm, 5분간 원심분리기(LABOGENE 1248, Korea)를 이용하여 원심분리를 진행한 후 상층액을 제거하였다. 비장세포액에 함유되어있는 적혈구를 제거하기 위해 RBC lysis buffer (Sigma aldrich. Korea)를 3ml 가해준 뒤 37℃ 항온수조에서 5분간 방치한 후 4℃, 1700 rpm에서 5분간 원심분리하였다. 분리된 상층액을 제거한 후 침전된 비장세포에 10% FBS (Gibco, USA)가 첨가된 RPMI-1640 (Gibco, USA) 배지액을 가하였다. After sacrificing the experimental animals, the spleen was removed, the surrounding tissue was removed, and then cut in half, and washed in a 15 mL cornical tube containing about 10 mL of 2% RPMI (Gibco, USA). After transferring to the Petri dish, the two slides are brought into contact with each other, applied pressure, crushed by rubbing, transferred to a cornical tube, and centrifuged using a centrifuge (LABOGENE 1248, Korea) at 4 ° C, 1700 rpm for 5 minutes, and then the upper layer liquid was removed. In order to remove the red blood cells contained in the splenocyte fluid, 3ml of RBC lysis buffer (Sigma aldrich. Korea) was added, and then left in a 37°C water bath for 5 minutes, followed by centrifugation at 4°C and 1700 rpm for 5 minutes. After removing the separated supernatant, RPMI-1640 (Gibco, USA) medium supplemented with 10% FBS (Gibco, USA) was added to the precipitated splenocytes.
6) 비장 세포 6) spleen cells 증식능proliferative capacity 측정 measurement
분리된 비장세포를 자동혈액분석기(Advia 2120i, SIEMENS, Germany)를 이용하여 살아있는 세포 수를 측정하였으며, 비장세포 증식능 측정을 위해 5X106 Cell/mL의 비장세포액이 되도록 조절하였다. 분리된 비장세포액을 96 well plate에 well 당 90 μL씩 가하고, 각 군당 mitogen으로 ConA (5μg/mL, Sigma aldrich. Korea), LPS (15μg/mL, Sigma aldrich. Korea)를 10 μL씩 분주하고 대조군에는 배지를 동량으로 분주한 뒤, 37℃, 5% CO2 incubator에서 44시간 동안 배양하였다. 배양 후 MTT (Gibco, USA)를 10 μL 가하고 알루미늄 호일로 빛을 차단한 상태에서 4시간 동안 다시 배양 후 formazan crystal 형성을 유도하였으며 4℃, 1500 rpm, 5분간 원심분리하여 상층액을 제거하고 각 well에 150 μL의 DMSO를 가하여 10분간 방치 하였다. 10분 후 ELISA reder (Multiscan GO, Thermo SCIENTIFIC, USA)를 이용하여 540 nm의 파장에서 흡광도를 측정한 뒤 sample의 흡광도/ control의 흡광도로 mouse 비장세포 증식능을 계산하였다. The number of live cells was measured using an automatic blood analyzer (Advia 2120i, SIEMENS, Germany) for the separated splenocytes, and 5X10 6 was used to measure the proliferation capacity of splenocytes. Cell/mL of spleen cell fluid was adjusted. 90 μL of the separated spleen cell fluid was added to each well in a 96-well plate, and 10 μL of ConA (5 μg/mL, Sigma aldrich. Korea) and LPS (15 μg/mL, Sigma aldrich. Korea) were dispensed as mitogens for each group, and the control group After dispensing the medium in the same amount, it was cultured for 44 hours in a 37°C, 5% CO 2 incubator. After incubation, 10 μL of MTT (Gibco, USA) was added and incubated again for 4 hours in the state of blocking light with aluminum foil to induce formazan crystal formation. The supernatant was removed by centrifugation at 4℃, 1500 rpm for 5 minutes, and each 150 μL of DMSO was added to the well and left for 10 minutes. After 10 minutes, the absorbance was measured at a wavelength of 540 nm using an ELISA redder (Multiscan GO, Thermo SCIENTIFIC, USA), and the mouse splenocyte proliferation capacity was calculated by the absorbance of the sample/absorbance of the control.
7) 림프구 아형 검사 7) Lymphocyte subtype test
비장세포액을 림프구 아형 검사 측정을 위해 1X106 Cell/100μL 비장세포액이 되도록 조절하였다. 조절된 비장세포액을 FACS Buffer (PBS contain 1% BSA) 1mL를 이용하여 4℃, 2000 rpm, 10분 조건으로 원심분리하여 2회 세척하였다. 상층액 제거 후, 남은 pellet을 각각 CD3, CD19, CD56 (BD, USA) 항체 mixture 100 μL로 현탁하여 빛을 차단한 채 4℃에서 30분간 반응시키고 상기 조건으로 2회 세척 하였다. 상층액 제거 후, 1% paraformaldehyde가 포함된 FACS buffer 200 μL를 이용해 pellet을 현탁시키고 ice에서 15분간 반응시킨 뒤, FACS buffer (PBS contain 1% BSA) 1 mL을 이용하여 2회 세척하였다. 상층액 제거 후, pellet을 FACS buffer 500 μL에 현탁시켜 FACS tube로 이동 후 측정하였다. The spleen cell fluid was adjusted to 1X10 6 Cell/100 μL spleen cell fluid for the measurement of lymphocyte subtype. The conditioned splenocyte fluid was washed twice using 1 mL of FACS Buffer (PBS containing 1% BSA) by centrifugation at 4°C, 2000 rpm, and 10 minutes. After removing the supernatant, the remaining pellet was suspended in 100 μL of CD3, CD19, and CD56 (BD, USA) antibody mixture, reacted for 30 minutes at 4°C while blocking light, and washed twice under the above conditions. After removing the supernatant, the pellet was suspended using 200 μL of FACS buffer containing 1% paraformaldehyde, reacted on ice for 15 minutes, and washed twice with 1 mL of FACS buffer (PBS containing 1% BSA). After removing the supernatant, the pellet was suspended in 500 μL of FACS buffer, moved to a FACS tube, and measured.
8) 8) ImmunoglobulinImmunoglobulin 측정 measurement
Immunoglobulin 측정을 위하여 복대동맥으로부터 채혈한 혈액을 응고촉진제가 들어있는 혈청 분리용 튜브인 SST tube (BD, USA)에 옮긴 후 미국 임상검사표준연구원 (USA, 2017) 기준에 따라 tube를 6~8회 위 아래로 혼합 후 실온에 30분간 방치하여 완전히 응고되도록 하였다. 응고된 혈액을 원심분리기 (LABOGENE 1248, Korea)를 이용하여 3000 rpm에서 10분간 원심분리 후 상층의 혈청을 분리하고 분석 전까지 -70℃에 보관하였다. Immunoglobulin(Ig) 측정을 위해 각 웰 당 Standard와 검체를 50 μL씩 분주한 뒤, HRP-conjugate를 50 μL 추가하고 잘 혼합 후 37℃에서 60분간 배양하였다. 각 웰을 Wash buffer를 이용해 5번 세척 한 후 90 μL의 TMB substrate를 넣고 빛이 차단된 상태에서 37℃, 20분간 배양하였다. 마지막으로 각 웰에 50 μL의 Stop solution을 넣고 플레이트를 혼합시킨 후 ELISA reader(Multiscan GO, Thermo SCIENTIFIC, USA)에서 450nm의 흡광도로 측정하였다. IgG, IgA, IgM 측정은 Mouse Immunoglobulin G/ A/ M ELISA Kit (Cusabio Biotech.,Co.Ltd., Wuhan, China)를 사용하여 실험하였다. For immunoglobulin measurement, the blood collected from the abdominal aorta was transferred to the SST tube (BD, USA), a tube for serum separation containing coagulation promoters, and then the tube was 6 to 8 times according to the standards of the US Institute of Standards for Clinical Laboratory Science (USA, 2017). After mixing up and down, it was allowed to stand at room temperature for 30 minutes to completely solidify. The coagulated blood was centrifuged at 3000 rpm for 10 minutes using a centrifuge (LABOGENE 1248, Korea), and then the serum in the upper layer was separated and stored at -70°C until analysis. For immunoglobulin (Ig) measurement, 50 μL of standard and sample were dispensed per well, 50 μL of HRP-conjugate was added, mixed well, and incubated at 37°C for 60 minutes. After washing each well 5 times with Wash buffer, 90 μL of TMB substrate was added and incubated at 37℃ for 20 minutes in a light-blocking state. Finally, 50 μL of Stop solution was added to each well, the plate was mixed, and the absorbance at 450 nm was measured in an ELISA reader (Multiscan GO, Thermo SCIENTIFIC, USA). IgG, IgA, and IgM were measured using Mouse Immunoglobulin G/A/M ELISA Kit (Cusabio Biotech., Co.Ltd., Wuhan, China).
9) 9) CytokineCytokine 측정 measurement
Cytokine 측정을 위하여 복대동맥으로부터 채혈한 혈액을 응고촉진제가 들어있는 혈청 분리용 튜브인 SST tube (BD, USA)에 옮긴 후 미국 임상검사표준연구원 (USA, 2017) 기준에 따라 tube를 6~8회 위 아래로 혼합 후 실온에 30분간 방치하여 완전히 응고되도록 하였다. 응고된 혈액을 원심분리기 (LABOGENE 1248, Korea)를 이용하여 3000 rpm에서 10분간 원심분리 후 상층의 혈청을 분리하고 분석 전까지 -70℃에 보관하였다. Cytokine 측정을 위해 각 웰 당 Standard와 검체를 100 μL씩 분주한 뒤, 37℃에서 2시간 동안 배양하였다. 각 웰의 액을 제거하고 100 μL의 Biotin antibody를 첨가한 뒤, 37℃을에서 1시간 동안 배양하였다. 각 웰을 Wash buffer를 이용해 3번 세척한 후, 100 μL의 HRP-avidin을 첨가하였으며 37℃에서 1시간 동안 방치하였다. 그 후 Wash buffer를 이용해 5번 세척을 진행하고, 각 웰에 50 μL의 Stop solution을 넣어 플레이트를 혼합시킨 후 ELISA reader(Multiscan GO, Thermo SCIENTIFIC, USA)에서 450nm의 흡광도로 측정하였다. IL-2, IFN-γ 측정은 Mouse ELISA Kit (Cusabio Biotech.,Co.Ltd., Wuhan, China)를 사용하여 실험하였다. For cytokine measurement, the blood collected from the abdominal aorta is transferred to the SST tube (BD, USA), a tube for serum separation containing coagulation promoters, and then the tube is 6 to 8 times according to the standards of the US Institute of Standards and Technology for Clinical Testing (USA, 2017) After mixing up and down, it was allowed to stand at room temperature for 30 minutes to completely solidify. The coagulated blood was centrifuged at 3000 rpm for 10 minutes using a centrifuge (LABOGENE 1248, Korea), and then the serum in the upper layer was separated and stored at -70°C until analysis. For cytokine measurement, 100 μL of standard and sample were dispensed per well, and incubated at 37℃ for 2 hours. After removing the liquid from each well and adding 100 μL of Biotin antibody, it was incubated for 1 hour at 37°C. After washing each well three times using Wash buffer, 100 μL of HRP-avidin was added and left at 37° C. for 1 hour. After that, the plate was washed 5 times using Wash buffer, 50 μL of Stop solution was added to each well, the plate was mixed, and the absorbance at 450 nm was measured in an ELISA reader (Multiscan GO, Thermo SCIENTIFIC, USA). IL-2 and IFN-γ were measured using Mouse ELISA Kit (Cusabio Biotech., Co. Ltd., Wuhan, China).
10) 조직병리학적 검사 10) Histopathological examination
시험 종료일에 절취한 비장 및 흉선을 10% 중성 포르말린에 24시간 고정하였다. 고정된 조직은 병리조직학적 검사를 위한 통상적인 방법을 사용하여 파라핀 포매 후, 4㎛ 두께로 연속절편하였다. 비장 및 흉선의 일반적인 형태변화를 관찰하기 위해 연속절편을 hematoxylin & eosin(H&E) 염색을 실시하여 광학현미경으로 관찰하였다. The spleen and thymus excised at the end of the test were fixed in 10% neutral formalin for 24 hours. The fixed tissues were serially sectioned at a thickness of 4 μm after paraffin embedding using a conventional method for histopathological examination. To observe general morphological changes in the spleen and thymus, serial sections were stained with hematoxylin & eosin (H&E) and observed under an optical microscope.
3. 통계처리3. Statistical processing
조직화학 및 면역조직화학 결과를 정량화하기 위해 image J program (Wayne Rasband, National Institutes of Health, Bethesada, MD, USA)을 이용하여 영상분석을 하였다. To quantify histochemical and immunohistochemical results, image analysis was performed using the image J program (Wayne Rasband, National Institutes of Health, Bethesada, MD, USA).
모든 실험 결과는 평균치와 표준오차로 나타내고, 각 군 간의 차이는 Student’s t-test SPSS v.20 (SPSS Inc. Chicago, IL. USA)을 사용하여 p<0.05일 때 통계적으로 유의성이 있다고 판정하였다.All experimental results were expressed as mean values and standard errors, and differences between groups were determined to be statistically significant when p <0.05 using Student's t- test SPSS v.20 (SPSS Inc. Chicago, IL. USA).
Ⅲ. 결과III. result
1. 실험동물 체중 변화 1. Changes in body weight of experimental animals
Cyclophosphamide의 투여와 발효사물탕을 함유한 기본 죽 투여에 따른 체중 변화를 알아보기 위하여, 3일 1회 측정하였다. Cyclophosphamide 투여 전 마우스의 무게를 측정한 후 평균 체중 32.9 ± 1.8 g에서 실험을 진행하였으며실험 종료 당일 최종 체중을 측정하였다. Cyclophosphamide 투여한 모든 군에서 체중이 감소하였으며, 시험물질 투여군의 경우 시간이 경과함에 따라 체중이 증가하였다. 특히, 발효사물탕 고농도 투여군에서 체중이 회복하는 결과를 나타냈으나, 유의성은 관찰되지 않았다(도 1) To investigate the change in body weight according to the administration of cyclophosphamide and the administration of basic porridge containing fermented samul-tang, it was measured once every 3 days. After measuring the weight of the mice before cyclophosphamide administration, the experiment was conducted at an average weight of 32.9 ± 1.8 g, and the final weight was measured on the day of the experiment. Body weight decreased in all groups administered with cyclophosphamide, and in the case of the test substance-administered group, body weight increased over time. In particular, in the high-concentration fermented samul-tang group, the weight was restored, but no significance was observed (FIG. 1).
2. 일반혈액검사 2. General blood test
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 적혈구 및 혈소판 지표의 영향을 평가하기 위하여 동물의 혈액에서 적혈구 수(red blood cell, RBC), 헤모글로빈(hemoglobin, Hgb, 헤마토크릿(hematocrit, HCT), 평균적혈구용적(mean corpuscular volume, MCV), 평균적혈구혈색소량(mean corpuscular hemoglobin, MCH), 평균적혈구 혈색소농도(mean corpuscular hemoglobin concentration, MCHC), 망상적혈구(reticulocyte, RETI), 백혈구 수 (white blood cell, WBC), 백혈구 백분율을 측정하였다(표 2). In order to evaluate the effect of the basic porridge containing cyclophosphamide and fermented sugar-tang on red blood cell and platelet parameters, the number of red blood cells (RBC), hemoglobin (Hgb, hematocrit (HCT)), mean mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte (RETI), white blood cell count WBC), white blood cell percentage was measured (Table 2).
정상대조군과 비교하여 보았을 때, 적혈구 수치는 cyclophosphamide를 투여한 면역억제군에서 유의하게 감소하였다(p<0.05). 발효사물탕을 함유한 기본 죽을 투여하였을 때, 면역억제군보다 농도에 따라 증가하였으나, 유의성은 나타나지 않았다(도 2). Compared to the normal control group, the red blood cell count was significantly decreased in the immunosuppressed group administered with cyclophosphamide ( p <0.05). When basic porridge containing fermented sugar-tang was administered, it increased according to the concentration than the immunosuppressed group, but no significance was shown (FIG. 2).
헤모글로빈은 정상대조군과 비교하여 보았을 때, 면역억제군에서 감소하였으나 유의성은 나타나지 않았다. 면역억제군과 시험물질 투여군을 비교하여 보았을 때, BM군에서 증가하는 경향을 보였으나, 유의성은 나타나지 않았다(표 2). Hemoglobin decreased in the immunosuppressed group when compared to the normal control group, but no significance was shown. When comparing the immunosuppressive group and the test substance administration group, there was a tendency to increase in the BM group, but no significance was shown (Table 2).
헤마토크릿, 평균 적혈구 용적, 평군적혈구혈색소량, 평균 적혈구 혈색소 농도는 정상대조군과 비교하여 보았을 때, 유의한 차이는 나타나지 않았다. 또한 면역억제군과 시험물질 투여군에서도 유의성을 도출할 수 없었다. There were no significant differences in hematocrit, mean red blood cell volume, average red blood cell hemoglobin level, and mean red blood cell hemoglobin concentration compared to the normal control group. In addition, significance could not be drawn in the immunosuppressive group and the test substance administration group.
망상적혈구 수는 정상대조군과 비교하여 보았을 때, 면역억제군에서 유의하게 증가하였다(p<0.05). 면역억제군과 시험물질 투여군을 비교하여 보았을 때 BM 군에서 유의하게 감소하는(p<0.05) 결과를 나타내었다(도 3). Reticulocyte count was significantly increased in the immunosuppressed group compared to the normal control group ( p <0.05). When comparing the immunosuppressive group and the test substance administration group, a significant decrease ( p <0.05) was shown in the BM group (FIG. 3).
백혈구 수는 정상대조군과 비교했을 때, 면역억제군에서 감소하였으나 유의한 차이는 나타나지 않았다. 반면, 면역억제군과 시험물질 투여군을 비교하였을 때, 양성 대조군과 BL군에서 증가하였으나 유의성은 관찰되지 않았다(표 2). Compared to the normal control group, the white blood cell count was decreased in the immunosuppressed group, but no significant difference was found. On the other hand, when the immunosuppressive group and the test material administration group were compared, it increased in the positive control group and the BL group, but no significance was observed (Table 2).
백혈구 백분율 중 림프구 비율은 정상대조군과 비교하였을 때 면역억제군에서 유의하게 감소하였다(p<0.05). 반면, 시험물질 투여군에서는 시험물질 농도에 따라 증가하는 경향을 보였으나 유의성은 나타나지 않았다(도 4). The percentage of lymphocytes in the white blood cell percentage was significantly decreased in the immunosuppressed group compared to the normal control group ( p <0.05). On the other hand, in the test substance administration group, there was a tendency to increase according to the test substance concentration, but no significance was shown (FIG. 4).
(X 10(X 10
33
//
μLμL
))
controlNormal
control
Hgb: hemoglobin, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, WBC: white blood cell. Data are shown as mean±SD (n=7).Hgb: hemoglobin, HCT: hematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin, MCHC: mean corpuscular hemoglobin concentration, WBC: white blood cell. Data are shown as mean±SD (n=7).
3. 혈액 생화학 검사3. Blood biochemistry test
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 영양학적 평가 생화학 지표의 영향을 평가하기 위하여 total protein (T.P), albumin (ALB), blood urea nitrogen (BUN) 농도를 측정하였다. Nutritional evaluation by administration of basic porridge containing cyclophosphamide and fermented samul-tang To evaluate the effect of biochemical indicators, total protein (TP), albumin (ALB), and blood urea nitrogen (BUN) concentrations were measured.
T.P 농도는 정상대조군과 비교하였을 때, 면역억제군에서 감소하였다. 반면, 시면역억제군과 시험물질 투여군을 비교하였을 때, 시험물질 투여군에서 증가하였다. (도 5). T.P concentration was decreased in the immunosuppressed group compared to the normal control group. On the other hand, when the immunosuppression group and the test substance administration group were compared, it increased in the test substance administration group. (FIG. 5).
ALB 농도는 정상대조군과 비교하였을 때, 면역억제군에서 감소하였으나 유의한 차이는 나타나지 않았다. 반면, 면역억제군과 시험물질 투여군을 비교하였을 때, 농도 의존적으로 증가하였으나 유의성은 도출할 수 없었다(도 6). ALB concentration was decreased in the immunosuppressed group compared to the normal control group, but no significant difference was found. On the other hand, when the immunosuppression group and the test material administration group were compared, it increased in a concentration-dependent manner, but significance could not be derived (FIG. 6).
Globulin 농도는 정상대조군과 비교하였을 때, 면역억제군에서 유의한 차이는 나타나지 않았다. 한편, 면역억제군과 시험물질 투여군을 비교하였을 때, 발효사물탕을 투여한 군에서 증가하였으나 유의성은 나타나지 않았다(도 7). There was no significant difference in the immunosuppressed group when compared to the normal control group. On the other hand, when comparing the immunosuppressive group and the test material administration group, it increased in the group administered with fermented samul-tang, but no significance was shown (FIG. 7).
BUN 농도의 경우 정상대조군과 비교하였을 때, 면역억제군에서 증가하였으나 유의성은 도출할 수 없었다. 반면, 시험물질 투여군에서는 면역억제군보다 감소하는 것을 관찰하였다(도 8). In the case of BUN concentration, compared to the normal control group, it increased in the immunosuppressed group, but significance could not be drawn. On the other hand, it was observed that the test substance administration group decreased than the immunosuppression group (FIG. 8).
4. 장기 중량 측정4. Long Term Weighing
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 면역력 개선 효과를 평가하기 위해 동물의 비장 및 흉선 조직에서 장기 중량을 측정하였다. 비장의 경우 정상대조군 0.27 ± 0.02 %와 비교하였을 때, 면역억제군 0.55 ± 0.04 %으로 유의하게 증가(p<0.05)하였다(도9). 한편, 시험물질 투여군에서 농도에 따라 감소하였으며 특히 BM 군에서 0.49 ± 0.14로 감소하는 것을 관찰하였으나, 유의성은 나타나지 않았다. In order to evaluate the effect of improving immunity by administering basic porridge containing cyclophosphamide and fermented samul-tang, organ weights were measured in spleen and thymus tissues of animals. In the case of the spleen, compared to 0.27 ± 0.02% of the normal control group, the immunosuppressed group significantly increased ( p <0.05) to 0.55 ± 0.04% (Fig. 9). On the other hand, it decreased according to the concentration in the test substance administration group, and in particular, it was observed that it decreased to 0.49 ± 0.14 in the BM group, but no significance was shown.
흉선의 경우 정상대조군 0.16 ± 0.03 %과 비교하였을 때, 면역억제군 0.15 ± 0.01 %로 감소하였으나 유의성은 나타나지 않았다. 한편, 면역억제군과 시험물질 투여군을 비교하였을 때 전체적으로 증가하였으나 유의한 차이는 나타나지 않았다(도10). In the case of the thymus, compared to 0.16 ± 0.03% of the normal control group, it decreased to 0.15 ± 0.01% of the immunosuppressed group, but no significance was shown. On the other hand, when the immunosuppressive group and the test substance administration group were compared, the overall increase was observed, but no significant difference was observed (FIG. 10).
5. 비장 세포 증식능 측정5. Measurement of spleen cell proliferation capacity
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 면역력 개선 효과를 평가하기 위해 동물의 비장 세포에서 B세포 및 T세포 증식능을 측정하였다. B세포 분열촉진인자인 LPS를 이용한 B세포 증식능을 측정한 결과, 정상대조군 6.08 ± 7.80 과 비교하였을 때, 면역억제군에서 0.91 ± 0.68로 현저하게 감소하였으나, 유의성은 나타나지 않았다. 반면, 면역억제군과 비교하였을 때, 발효사물탕을 투여한 군에서 모두 농도 의존적으로 증가하는 효과를 보였으며, 특히 BH 5.24 ± 3.47 pg/mL로 유의하게 증가(p<0.05)하였다(도 11). T세포 분열촉진인자인 ConA를 이용한 T세포 증식능을 측정한 결과, 정상대조군 4.62 ± 6.55과 비교하였을 때, 면역억제군에서 1.68 ± 1.56으로 현저하게 감소하였으나 유의성은 나타나지 않았다. 한편, 면역억제군과 비교하였을 때, 발효사물탕을 투여한 군에서 모두 농도 의존적으로 증가하는 효과를 보였으나 유의한 차이는 나타나지 않았다(도 12). To evaluate the effect of improving immunity by administering basic porridge containing cyclophosphamide and fermented samul-tang, B cell and T cell proliferative abilities were measured in animal spleen cells. As a result of measuring the B cell proliferative ability using LPS, a B cell mitogen, it was significantly reduced to 0.91 ± 0.68 in the immunosuppressed group compared to 6.08 ± 7.80 in the normal control group, but no significance was shown. On the other hand, compared to the immunosuppressive group, all groups administered with fermented sugar-tang showed a concentration-dependent increase, and in particular, BH was significantly increased ( p <0.05) to 5.24 ± 3.47 pg/mL (FIG. 11). . As a result of measuring the T cell proliferative ability using ConA, a T cell mitogen, it was significantly reduced to 1.68 ± 1.56 in the immunosuppressed group compared to 4.62 ± 6.55 in the normal control group, but no significance was shown. On the other hand, when compared with the immunosuppressive group, the group administered with fermented samul-tang showed an increasing effect in a concentration-dependent manner, but no significant difference was observed (FIG. 12).
6. 림프구 아형 검사 6. Lymphocyte subtyping
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 면역력 개선 효과를 평가하기 위해 동물의 비장 세포에서 림프구 아형 검사를 진행하였다. B세포를 보기 위한 CD 19, T세포를 보기 위한 CD3, NK 세포를 보기 위한 CD 56을 측정하였다. CD 19를 측정한 결과, 정상 대조군 1245.2 ± 571.5 ng/mL과 비교하였을 때, 면역억제군에서 785.2 ± 241.0 ng/mL로 감소하였으나 유의성은 나타나지 않았다. 반면, 면역억제군과 비교하였을 때 시험물질 투여군에서 농도 의존적으로 증가하였으며, 특히 BH군에서 996.4 ± 190.5 ng/mL로 증가하였으나 유의한 차이는 나타나지 않았다(도 13). CD 3을 측정한 결과, 정상대조군 570 ± 172.8 ng/mL와 비교하였을 때, 면역억제군에서 390.1 ± 22.2 ng/mL로 감소하였으나 유의한 차이는 나타나지 않았다. 한편 면역억제군과 비교하였을 때, 시험물질 투여군에서 농도 의존적으로 증가하였으며, 특히 BH군에서 537.3 ± 115.7 ng/mL로 유의하게 증가(p<0.05)하였다(도 14). CD 56을 측정한 결과 정상대조군 34.3 ± 15.8 ng/mL과 비교하였을 때, 면역억제군에서 24.5 ± 6.8로 감소하였으나 유의한 차이는 나타나지 않은 반면, 면역억제군과 시험물질 투여군을 비교하였을 때, 농도 의존적으로 증가하였다. 특히, BH 군에서 36.3 ± 8.0 ng/mL로 유의하게 증가(p<0.05)하였다(도 15). In order to evaluate the immune improvement effect of the basic porridge containing cyclophosphamide and fermented samul-tang, a lymphocyte subtype test was performed in the animal's spleen cells.
7. 면역글로불린 검사7. Immunoglobulin test
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 면역력 개선 효과를 평가하기 위해 동물의 혈청에서 면역글로불린 검사를 진행하였다. 눈물이나 침 등 체액에서 분비되어 점막 표면을 보호하는 면역글로불린 A, 보체 매개성 용해 및 항원 항체 복합체 형성 등에 의한 탐식기능 역할을 하는 면역글로불린 M, 박테리아와 같은 병원체를 인식하여 탐식 가능하도록 하는 기능을 하는 면역글로불린 G를 측정하였다. 면역글로불린 A를 측정한 결과, 정상대조군 480 ± 131 ng/mL과 비교하였을 때, 면역억제군에서 48 ± 69 ng/mL로 현저하게 감소하였으며 유의한 결과를 나타내었다(p<0.05). 반면, 면역억제군과 시험물질 투여군을 비교하였을 때, BM군 372 ± 173 ng/mL, BH군 220 ± 212 ng/mL로 유의하게 증가(p<0.05)하였다(도 16). 또한, 발효사물탕 투여군 모두 면역억제군과 비교하였을 때 20% 이상 증가하는 결과를 보였다. In order to evaluate the effect of improving immunity by administration of basic porridge containing cyclophosphamide and fermented samul-tang, immunoglobulin test was performed in animal serum. Immunoglobulin A secreted from bodily fluids such as tears or saliva to protect mucosal surfaces, immunoglobulin M that plays a role in phagocytosis by complement-mediated lysis and formation of antigen-antibody complexes, etc. Immunoglobulin G was measured. As a result of measuring immunoglobulin A, compared to 480 ± 131 ng/mL in the normal control group, it was significantly reduced to 48 ± 69 ng/mL in the immunosuppressed group, showing a significant result ( p <0.05). On the other hand, when the immunosuppressive group and the test substance administration group were compared, the BM group 372 ± 173 ng/mL and the BH group 220 ± 212 ng/mL increased significantly ( p <0.05) (FIG. 16). In addition, all groups treated with fermented sugar-tang showed an increase of more than 20% compared to the immunosuppressed group.
면역글로불린 M을 측정한 결과, 정상대조군 190 ± 69 ng/mL과 비교하였을 때, 면역억제군에서 177 ± 92 ng/mL로 감소하였으나 유의한 차이는 나타나지 않았다. 반면, 면역억제군과 비교하였을 때, 시험물질 투여군에서 증가하였으며 특히 SM군에서 316 ± 149 ng/mL로 증가하였으나 유의성은 나타나지 않았다(도 17). As a result of measuring immunoglobulin M, compared to 190 ± 69 ng/mL in the normal control group, it decreased to 177 ± 92 ng/mL in the immunosuppressed group, but no significant difference was observed. On the other hand, when compared to the immunosuppressive group, it increased in the test substance administration group, especially in the SM group, but increased to 316 ± 149 ng / mL, but no significance was shown (FIG. 17).
면역그로불린 G를 측정한 결과, 정상대조군 1258 ± 442 ng/mL과 비교하였을 때, 면역억제군에서 646 ± 209 ng/mL로 현저하게 감소하였으며 유의성 있는 결과를 나타내었다(도18). 반면, 면역억제군과 시험물질 투여군을 비교하였을 때, 모두 증가하였으며 BM, BH군에서 20% 이상 증가하는 결과를 보였다. As a result of measuring immunoglobulin G, compared to 1258 ± 442 ng/mL in the normal control group, it was significantly reduced to 646 ± 209 ng/mL in the immunosuppressed group, showing significant results (FIG. 18). On the other hand, when comparing the immunosuppressive group and the test material administration group, both increased, and the BM and BH groups showed a result of increasing by more than 20%.
8. 8. CytokineCytokine 검사 test
Cyclophosphamide와 발효사물탕을 함유한 기본죽 투여에 의한 면역력 개선 효과를 평가하기 위해 동물의 혈청에서 cytokine 검사를 진행하였다. Th-1 세포에 의하여 분비되는 cytokine으로 NK 세포 활성 인자로 알려진 INF-γ와 CD 4 T세포에서 생성되며, T세포의 생존과 증식에 관여하는 IL-2를 측정하였다. INF-γ를 측정한 결과, 정상대조군과 비교하였을 때, 면역억제군에서 유의한 차이는 나타나지 않았다. 한편, 면역억제군과 비교하였을 때, 시험물질 투여군 중 BH군에서 증가하였으나 유의한 결과는 나타나지 않았다(도 19). In order to evaluate the effect of improving immunity by administering basic porridge containing cyclophosphamide and fermented sugar-tang, cytokine test was performed on the serum of animals. INF-γ, a cytokine secreted by Th-1 cells and known as an NK cell activator, and IL-2, which is produced in CD 4 T cells and involved in T cell survival and proliferation, were measured. As a result of measuring INF-γ, there was no significant difference in the immunosuppressed group compared to the normal control group. On the other hand, when compared to the immunosuppressive group, it increased in the BH group among the test substance administration groups, but no significant results were shown (FIG. 19).
IL-2를 측정한 결과, 정상대군과 비교하였을 때, 면역억제군에서 유의한 차이는 나타나지 않았다. 반면, 시험물질 투여군 중 BH군에서 유의하게 증가(p<0.05)하는 결과를 보였다(도 20). As a result of measuring IL-2, there was no significant difference in the immunosuppressed group compared to the normal group. On the other hand, a significant increase ( p <0.05) was shown in the BH group among the test substance administration groups (FIG. 20).
9. 조직병리학적 검사 9. Histopathological examination
haematoxylin & Eosin (H&E) 염색을 통하여 비장 및 흉선의 병리학적 변화를 관찰하였다 (도 21,23). 비장의 경우 정상대조군에서는 특이할 만한 조직병리학적 소견은 관찰되지 않았으나 면역억제군에서 감염과 싸우는 면역 기능을 가지고 있어 림프구를 통해 항체를 생성하는데 관여하는 백색속질의 비율이 현저하게 감소하였다. 반면, 면역억제군 19.4 ± 4.9 %와 비교하였을 때, 시험물질 투여군에서 농도 의존적으로 증가하였으며 특히 BM 39.8 ± 7.4 %, BH 44.0 ± 9.6 % 군에서 유의하게 증가(p<0.05)하였다(도 22). 흉선의 경우 정상 대조군에서는 특이할 만한 조직병리학적 소견은 관찰되지 않았으나 면역억제군에서 수질이 차지하는 면적의 비율이 유의하게 감소(p<0.05)하여 위축이 일어난 것을 확인하였다. 반면, 면역억제군과 비교하였을 때, 시험물질 투여군에서 증가하였으나 유의한 차이는 나타나지 않았다(도 24). Pathological changes in the spleen and thymus were observed by haematoxylin & Eosin (H&E) staining (FIGS. 21 and 23). In the case of the spleen, no specific histopathological findings were observed in the normal control group, but the percentage of white matter involved in antibody production through lymphocytes was significantly reduced in the immunosuppressed group because it had an immune function to fight infection. On the other hand, compared to 19.4 ± 4.9% of the immunosuppression group, the test substance administration group increased in a concentration-dependent manner, and in particular, it increased significantly ( p <0.05) in the BM 39.8 ± 7.4% and BH 44.0 ± 9.6% groups (Fig. 22) . In the case of the thymus, no specific histopathological findings were observed in the normal control group, but in the immunosuppressed group, the area occupied by the medulla significantly decreased ( p <0.05), confirming that atrophy occurred. On the other hand, when compared to the immunosuppressive group, it increased in the test substance administration group, but no significant difference was observed (FIG. 24).
본 발명은 상기한 구성과 작용 및 효과로 이루어진 면역력 증진 기능이 있는 발효사물탕 죽의 제조방법 및 그에 따른 면역력 증진 기능이 있는 발효사물탕 죽을 제공한다.The present invention provides a method for manufacturing fermented samul-tang porridge having an immunity enhancing function composed of the above configuration, action and effect, and a fermented samul-tang porridge having an immunity enhancing function accordingly.
본 발명은 기능성 죽을 생산, 제조, 판매, 유통, 연구하는 산업에 매우 유용하다.The present invention is very useful for industries that produce, manufacture, sell, distribute, and research functional porridge.
특히, 본 발명은 천연의 재료를 이용하여 면역력을 증강시키는 기능성 죽을 생산, 제조, 판매, 유통, 연구하는 산업에 매우 유용하다.In particular, the present invention is very useful for industries that produce, manufacture, sell, distribute, and research functional porridge that enhances immunity using natural ingredients.
Claims (3)
상기한 발효사물탕은 숙지황, 작약, 천궁, 당귀를 혼합하여 추출한 조성물을 준비하는 과정을 포함하되,
상기의 혼합한 원재료 100 중량부를 70~90중량% 알코올 1000~2000 중량부에 넣고 2~5시간 동안 환류 추출한 것을 여과하여 준비하고,
상기의 추출 조성물에 L.delbruekil, L.acidophilus, L.casei 및 S.thermophilus 균을 접종시켜 발효시키는 과정으로 제조한 것으로서,
상기의 추출 조성물에 첨가 조성물을 혼합하고 상기의 균을 접종하여 30~40도씨에서 20~138시간 발효시키며,
상기한 첨가 조성물은 둥글레 100중량부에 질경이 50~150중량부, 오미자 50~150 중량부, 맥문동 20~50 중량부, 석창포 20~50중량부, 길경 50~150중량부, 의이인 50~150중량부, 감잎 50~150중량부를 혼합하여 추출한 조성물이고,
상기한 발효사물탕은 통상의 죽에 0.01~20중량%가 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽.
Fermented sugar water is included in normal porridge,
The above-mentioned fermented samul-tang includes the process of preparing a composition extracted by mixing sukjihwang, peony, cnidium, and angelica,
100 parts by weight of the above mixed raw materials was added to 1000 to 2000 parts by weight of 70 to 90% alcohol by weight, and the reflux extraction was prepared by filtering for 2 to 5 hours,
It is prepared by inoculating and fermenting L.delbruekil, L.acidophilus, L.casei and S.thermophilus bacteria in the above extract composition,
Mix the additive composition with the above extraction composition and inoculate the above bacteria to ferment at 30 to 40 degrees Celsius for 20 to 138 hours,
The above additive composition is 50 to 150 parts by weight of plantain, 50 to 150 parts by weight of Schisandra chinensis, 20 to 50 parts by weight of Maekmundong, 20 to 50 parts by weight of Seokchangpo, 50 to 150 parts by weight of Gilkyung, and 50 to 150 parts by weight of Uiyin. It is a composition extracted by mixing 50 to 150 parts by weight of persimmon leaves,
The above fermented samul-tang is a fermented samul-tang porridge with an immunity enhancing function, characterized in that it contains 0.01 to 20% by weight in normal porridge.
발효사물탕을 준비하는 과정(2과정)을 수행하되,
상기한 발효사물탕은 숙지황, 작약, 천궁, 당귀를 혼합하여 추출한 조성물을 준비하는 과정을 수행하되,
상기의 혼합한 원재료 100 중량부를 70~90중량% 알코올 1000~2000 중량부에 넣고 2~5시간 동안 환류 추출한 것을 여과하여 준비하고,
상기의 추출 조성물에 L.delbruekil, L.acidophilus, L.casei 및 S.thermophilus 균을 접종시켜 발효시키는 과정으로 제조한 것으로서,
상기의 추출 조성물에 첨가 조성물을 혼합하여 상기의 균을 접종하여 30~40도씨에서 20~138시간 발효시키며,
상기한 첨가 조성물은 둥글레 100중량부에 질경이 50~150중량부, 오미자 50~150 중량부, 맥문동 20~50 중량부, 석창포 20~50중량부, 길경 50~150중량부, 의이인 50~150중량부, 감잎 50~150중량부를 혼합하여 추출한 조성물이며,
상기에서 준비한 죽과 발효사물탕을 혼합하는 과정(3과정)을 수행하되,
상기한 발효사물탕은 통상의 죽에 0.01~20중량%가 포함된 것을 특징으로 하는 면역력 증진 기능이 있는 발효사물탕 죽의 제조 방법.
The process of preparing porridge (Course 1),
Perform the process of preparing fermented sugar tang (step 2),
The fermented samul-tang described above performs the process of preparing a composition extracted by mixing sukjihwang, peony, cnidium, and angelica,
100 parts by weight of the above mixed raw materials was added to 1000 to 2000 parts by weight of 70 to 90% alcohol by weight, and the reflux extraction was prepared by filtering for 2 to 5 hours,
It is prepared by inoculating and fermenting L.delbruekil, L.acidophilus, L.casei and S.thermophilus bacteria in the above extract composition,
Mix the additive composition with the above extraction composition, inoculate the above bacteria, and ferment at 30 to 40 degrees Celsius for 20 to 138 hours,
The above additive composition is 50 to 150 parts by weight of plantain, 50 to 150 parts by weight of Schisandra chinensis, 20 to 50 parts by weight of Maekmundong, 20 to 50 parts by weight of Seokchangpo, 50 to 150 parts by weight of Gilkyung, and 50 to 150 parts by weight of Uiyin. It is a composition extracted by mixing 50 to 150 parts by weight of persimmon leaves,
Perform the process (step 3) of mixing the porridge prepared above and the fermented samul-tang,
The method for producing fermented samul-tang porridge with immunity enhancing function, characterized in that the fermented samul-tang contains 0.01 to 20% by weight in normal porridge.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200005790A KR102485587B1 (en) | 2020-01-16 | 2020-01-16 | a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200005790A KR102485587B1 (en) | 2020-01-16 | 2020-01-16 | a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210092425A KR20210092425A (en) | 2021-07-26 |
KR102485587B1 true KR102485587B1 (en) | 2023-01-06 |
Family
ID=77124802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200005790A KR102485587B1 (en) | 2020-01-16 | 2020-01-16 | a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102485587B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040096957A (en) * | 2004-09-30 | 2004-11-17 | 김경석 | Functional Korean traditional Folk medicine for cooking Gorridge method. |
KR20170120053A (en) * | 2017-10-12 | 2017-10-30 | 서창산업주식회사 | the fermented samultang extracting method with the function of both anti-oxidation and immunity and the samultang extract using thereof |
KR102111665B1 (en) * | 2018-05-18 | 2020-05-15 | 주식회사 씨월드 | Method for producing oriental medicinal meat broth for instant gruel of powder type and oriental medicinal meat broth for instant gruel produced by the same method |
-
2020
- 2020-01-16 KR KR1020200005790A patent/KR102485587B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
3. 사물탕찹쌀죽으로 혈을 보하다. 네이버 블로그. 2013.04.24., [2021.06.04. 검색], 인터넷: <URL: https://blog.naver.com/zittacafe/50170104721> 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20210092425A (en) | 2021-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100651703B1 (en) | Tablet milk composition having immuno-modulating activity and preparation method thereof | |
KR930002022B1 (en) | Process for the production of kefir yoghurt | |
Chen et al. | Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells | |
WO2016127749A1 (en) | Lactic acid bacteria fermented flour, preparation method and use thereof | |
CN107242295B (en) | Preparation method of purple sweet potato yoghourt | |
Jain et al. | Development of low cost nutritional beverage from whey | |
KR101158506B1 (en) | Fermented ginseng yoghurt drink composition and preparation method thereof | |
CN113142303A (en) | Yoghourt with obesity preventing effect and preparation method thereof | |
KR102485587B1 (en) | a fermented samultang soup making method with the function of immunity enhancement and the fermented samultang soup making method | |
CN103431466A (en) | Ginseng solid beverage and preparation method thereof | |
CN111972494A (en) | Sports nutritional milk powder and preparation method thereof | |
CN113854574B (en) | Novel compound bone peptide and application thereof | |
KR20230019893A (en) | a sagunjatang soup making method with the function of immunity enhancement and the sagunjatang soup making method | |
KR101729827B1 (en) | Garlic stem powder and tablet manufacturing method using thereof | |
KR100902947B1 (en) | Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion | |
CN105794971A (en) | Functional drinking type yogurt and preparation method thereof | |
CN111560406A (en) | Method for producing flavonoid substances from external products such as soybeans for bacillus natto fermented vegetables | |
KR101771075B1 (en) | Composition for improving immune functions comprising extracts of fermented Arctium lappa L.and Spinacia oleracea | |
Lin et al. | Proteinaceous constituents of red cabbage juice increase IL-10, but decrease TNF-α secretions using LPS-stimulated mouse splenocytes | |
KR100758244B1 (en) | Fermented Milk Containing Acanthopanax Senticosus and Manufacturing Method thereof | |
KR20200086408A (en) | Grain snack manufacturing method using allergy reducing material and Grain snack manufactured by the method | |
KR20160006475A (en) | Chestnut drink and producing method thereof | |
TWI750817B (en) | Preparation method of tremella composition and tremella composition | |
KR102671197B1 (en) | A food composition comprising extracts of sand lance for enhancing immunity | |
Kontareva et al. | Improving the environmental safety of dairy products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |